Form 4: FRACTYL CFO Granted Over 1 Million Stock Options

FRACTYL HEALTH, INC. Chief Financial Officer Lara Smith Weber was granted 1,036,800 stock options with an exercise price of $2, vesting over four years.

Summary

• Lara Smith Weber, Chief Financial Officer of FRACTYL HEALTH, INC. (GUTS), acquired 1,036,800 stock options.
• The transaction date for this grant was January 12, 2026.
• Each stock option has an exercise price of $2.
• The options vest as to 25% of the shares on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.
• Vesting is contingent upon Ms. Smith Weber's continuous service with the company.
• The options have an expiration date of January 11, 2036.
• The transaction was made pursuant to a Rule 10b5-1(c) plan for the purchase or sale of equity securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, as it aligns management's incentives with shareholder interests. However, it is a routine compensation event rather than a direct indicator of immediate financial performance or strategic breakthrough, hence a moderately positive score.

Positives

• The grant of 1,036,800 stock options aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing performance and growth.
• The establishment of a Rule 10b5-1 plan demonstrates a pre-planned approach to equity transactions, potentially reducing concerns about opportunistic insider trading.

Negatives

• The stock options do not represent immediate equity ownership and are subject to a vesting schedule, meaning the full benefit is not realized upfront.
• The value of the options is dependent on the future performance of FRACTYL HEALTH, INC.'s common stock, introducing market risk.

Risks

• The value of the stock options is subject to market volatility, and if the company's stock price does not exceed the $2 exercise price, the options may expire worthless.
• The options are subject to forfeiture if the reporting person's continuous service with the company terminates before the vesting dates.

Future Outlook

The stock option grant is a standard component of executive compensation, designed to incentivize long-term performance and align management's financial interests with shareholder value creation over the next decade, subject to the company's stock performance and the CFO's continued service.

Industry Context

Equity compensation, particularly stock option grants with multi-year vesting schedules, is a common practice in the biotechnology and health technology sectors. It serves to attract and retain key talent, motivate long-term strategic execution, and link executive rewards directly to company performance and shareholder returns.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer with a multi-year vesting schedule is a standard form of equity compensation, comparable to practices at other growth-stage companies in the biotech and health tech industries.
• The use of a Rule 10b5-1 plan for such transactions is also a common corporate governance practice, enhancing transparency and mitigating concerns about insider trading.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the CFO's financial incentives with long-term shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: This grant is part of the company's executive compensation structure, which can influence overall compensation philosophy and employee morale.

Next Steps

• The stock options will begin vesting on January 12, 2027, with subsequent monthly vesting installments.
• The Chief Financial Officer will continue to hold these options, subject to continuous service, until their expiration on January 11, 2036, or earlier exercise.

Key Dates

Keywords

FRACTYL HEALTH, GUTS, Stock Option, CFO, Lara Smith Weber, Insider Transaction, Equity Compensation, Form 4, SEC Filing, Rule 10b5-1